Arecor and GSK form collaboration to advance new vaccines

Arecor and GSK form collaboration to advance new vaccines
Tuesday 14 June 2011
Arecor and GSK form collaboration to advance new vaccines
CAMBRIDGE, ENGLAND. 13TH APRIL, 2010: 08:00 EST

 

Arecor and GSK have entered into a license agreement to develop advanced formulations of vaccines combining Arecor's unique formulation technologies with GSK's proprietary vaccines. GSK and Arecor have collaborated to develop new approaches which could offer significant improvements to the administration of several vaccines in development. In return for the license to their technology, Arecor will receive payments on relevant development milestones and royalties on sales.

 

Tom Saylor, CEO of Arecor stated "Arecor is pleased to work closely with one of the global leaders in vaccine products and technology. The relationship with GSK offers Arecor the potential to apply its broad-ranging expertise in biomolecule stabilisation to specific projects with GSK."

 

Arecor Limited was established to provide formulation solutions to pharmaceutical and biotech companies developing proteins, vaccines and diagnostics based upon new insights into stabilization of biologics. Proteins and vaccines are often fragile entities, and stability can represent significant constraints in the development of new products and extending the use of existing products. Arecor has developed ArestatTM, a patented set of tools for stabilization which address the main pathways of degradation. As a simple reformulation, ArestatTM can be readily incorporated into standard manufacturing practice, without covalent modification of the biologic and using excipients approved for the route of delivery. Arecor currently has active feasibility programs and licenses with many of the top pharmaceutical and biotech companies on a wide range of proteins and vaccines.

 


-End-

 

-Contact: Tom Saylor, CEO [email protected]

Suggested Articles

German viral vector CDMO Vibalogics has hired Lonza veteran Tom Hochuli as global CEO to help lead its U.S. expansion efforts.

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.